Graham Cooper barrels in as Geron CFO
This article was originally published in Clinica
Geron Corporation has appointed Graham Cooper executive vice-president of finance and business development and chief financial officer. From 2006 to 2011, Mr Cooper served as senior vice-president, CFO and treasurer of Orexigen Therapeutics, where he was instrumental in growing the company from a venture-backed start-up into a sizeable public company. Geron recently put its stem cell assets up for sale, and dropped its clinical programme for GRNOPC1, a stem cell therapy for acute spinal cord injury that had been in a Phase I trial (www.clinica.co.uk, 15 November 2011). The company now plans to concentrate on its drugs imetelstat and GRN1005, which are in Phase II studies.